Insmed initiates three Phase 3 trials of TPIP for pulmonary diseases
Bitget2026/10/15 11:06- Insmed will feature its four-study Phase 3 PALM program for treprostinil palmitil inhalation powder at CHEST 2026.
- Three trials have begun; the fourth, PALM-IPF, is expected to start in the first half of 2027.
- The program aims to enroll more than 2,000 patients to evaluate once-daily treatment for pulmonary hypertension and fibrotic lung diseases.
- Earlier Phase 2 studies yielded clinically meaningful efficacy and safety findings in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.
- The Phase 3 trials will assess whether treatment improves exercise capacity or preserves lung function across the targeted diseases.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.
Why Nintendo Stock Is One to Watch Ahead of the Holiday Season
A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.
Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.
Crypto prices
More
